Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.58 |
| ▸ | NPY1R | P25929 | 3/20 | 0.56 |
| ▸ | NPY2R | P49146 | 3/20 | 0.56 |
| ▸ | NPY4R | P50391 | 3/20 | 0.56 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 4/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933760 | 1.00 | GHSR (0.58) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL2946041 | 0.94 | ERAP2 (0.59) | GHSRUTS2RERAP2ECE1 | |
| SCHEMBL16332701 | 0.91 | ERAP2 (0.62) | GHSRERAP2ECE1 | |
| SCHEMBL15391980 | 0.91 | ERAP2 (0.62) | GHSRERAP2ECE1 | |
| SCHEMBL30179257 | 0.90 | ERAP2 (0.58) | GHSRERAP2ECE1 | |
| SCHEMBL31202576 | 0.90 | GHSR (0.66) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL30198541 | 0.89 | ERAP2 (0.59) | GHSRERAP2 | |
| SCHEMBL31211837 | 0.89 | ERAP2 (0.59) | GHSRUTS2RERAP2ECE1 | |
| SCHEMBL30688843 | 0.88 | GHSR (0.65) | GHSRUTS2R | |
| SCHEMBL31666000 | 0.87 | ERAP2 (0.58) | GHSRNPY1RNPY2RNPY4RERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697401-B1 | TETRAPEPTIDE REGULATING BLOOD GLUCOSE LEVEL IN DIABETES MELLITUS | ACCESS BIOSCIENCE CJSC (RU) | 2010-01-06 | — | — | EP | claimed |
| US-20070142298-A1 | Tetrapeptide regulating blood glucose level in diabetes mellitus | SANKT-PETERBURGSKAYA OBSCHESTVENNAYA ORGANIZATSIYA "SANKT-PETERBURGSKIY INSTITUT BIOREG (RU) | 2007-06-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142298-A1 | Tetrapeptide regulating blood glucose level in diabetes mellitus | DNPEP, AADAT, ANPEP | GHSR 364/4885NPY1R 202/4885NPY2R 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.